Nos Publications

Retrouvez tous nos travaux de Recherche
2019

Vialaret J, Lehmann S, Hirtz C.
Methods Mol Biol. 2019;1959:163-172, https://www.ncbi.nlm.nih.gov/pubmed/30852822
Intact Protein Analysis by LC-MS for Characterizing Biomarkers in Cerebrospinal Fluid.

Lepleux C, Marie-Brasset A, Temelie M, Boulanger M, Brotin E,  Goldring MB, Hirtz C, Varès G, Nakajima T, Saintigny Y, Savu D, Chevalier F.
Journal of Cell Communication and Signaling, https://www.ncbi.nlm.nih.gov/pubmed/30903603
Bystander effectors of chondrosarcoma cells irradiated at different LET impair proliferation of chondrocytes.

Relaño-Ginés A, Lehmann S, Deville de Périère D, Hirtz C.
Crit Rev Clin Lab Sci. 2019 May;56(3):170-181, https://www.ncbi.nlm.nih.gov/pubmed/30931658
Dental stem cells as a promising source for cell therapies in neurological diseases.

Peyron PA, Lehmann S, Delaby C, Baccino E, Hirtz C.
Crit Rev Clin Lab Sci. (2019) In press (IF 6.481), https://www.ncbi.nlm.nih.gov/pubmed/31088325
Biochemical markers of time since death in cerebrospinal fluid: a first step towards “Forensomics”.

Paterson RW, Gabelle A, Lucey BP, Barthélemy NR, Leckey CA, Hirtz C, Lehmann S, Sato C, Patterson BW, West T, Yarasheski K, Rohrer JD, Wildburger NC, Schott JM, Karch CM, Wray S, Miller TM, Elbert DL, Zetterberg H, Fox NC, Bateman RJ.
Nat Rev Neurol. 2019 Jul;15(7):419-427, https://www.ncbi.nlm.nih.gov/pubmed/31222062
SILK studies – capturing the turnover of proteins linked to neurodegenerative diseases.

Murall CL, Rahmoun M, Selinger C, Baldellou M, Bernat C, Bonneau M, Boué V, Buisson M, Christophe G, D’Auria G, Taroni F, Foulongne V, Froissart R, Graf C, Grasset S, Groc S, Hirtz C, Jaussent A, Lajoie J, Lorcy F, Picot E, Picot MC, Ravel J, Reynes J, Rousset T, Seddiki A, Teirlinck M, Tribout V, Tuaillon É, Waterboer T, Jacobs N, Bravo IG, Segondy M, Boulle N, Alizon S.
BMJ Open. 2019 Jun 11;9(6):e025129. doi: 10.1136/bmjopen-2018-025129, https://www.ncbi.nlm.nih.gov/pubmed/31189673
Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study.

Pontier D, Picart C, El Baidouri M, Roudier F, Xu T, Lahmy S, Llauro C, Azevedo J, Laudié M, Attina A, Hirtz C, Carpentier MC, Shen L, Lagrange T.
Life Sci Alliance. 2019 May 29;2(3), https://www.ncbi.nlm.nih.gov/pubmed/31142640
The m6A pathway protects the transcriptome integrity by restricting RNA chimera formation in plants.

Contreras-Aguilar MD, Vialaret J, de Périère DD, Escribano D, Lehmann S, Tecles F, Cerón JJ, Hirtz C.
Clin Oral Investig. 2019 Aug 6. doi: 10.1007/s00784-019-03021-9, https://www.ncbi.nlm.nih.gov/pubmed/31388762
Variation of human salivary alpha-amylase proteoforms in three stimulation models.

Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, Pageot N, Esselin F, Alphandéry S, Vincent T, Camu W.
Eur J Neurol. 2019 Aug 22. doi: 10.1111/ene.14063, https://www.ncbi.nlm.nih.gov/pubmed/31437330
Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.

2018
Vialaret J, Wessels H, van Gool AJ, Lehmann S, Gabelle A, Wood J, Bern M, Paape R, Suckau D, Kruppa G and C Hirtz.
Journal of Proteomics (IF :3.88). 2018 Mar 20;175:12-26, https://www.ncbi.nlm.nih.gov/pubmed/28855124
Towards a routine application of Top-Down approaches for Label-Free discovery Workflows.
Mertens B, Orti V, Vialaret J, Gibert P, Relaño-Ginés A, Lehmann S, de Périère DD, Hirtz C.
Bioanalysis. 2018 Jan;10(1):35-45. doi: 10.4155/bio-2017-0218 (IF:2.7), https://www.ncbi.nlm.nih.gov/pubmed/29243487
Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples.
Dauvilliers Y, Chenini S, Vialaret J, Delaby C, Guiraud L, Gabelle A, Lopez R, Hirtz C, Jaussent I, Lehmann S.
Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27287, https://www.ncbi.nlm.nih.gov/pubmed/29418021
Association between serum hepcidin level and restless legs syndrome.
Vialaret J, Picas A, Delaby C, Bros P, Lehmann S, Hirtz C.
Journal of Chromatography B. 2018, Vol 1086: 110-117, https://www.ncbi.nlm.nih.gov/pubmed/29660664
Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?
Orti V, Mertens B, Vialaret J, Gibert P, Relaño-Ginés A, Lehmann S, de Périère DD, Hirtz C.
Data in Brief. 2018, Vol 18, Pages 294-299, https://www.ncbi.nlm.nih.gov/pubmed/29900194
Data from a targeted proteomics approach to discover biomarkers in saliva for the clinical diagnosis of periodontitis.
Vialaret J, Wessels H, van Gool AJ, Lehmann S, Gabelle A, Wood J, Bern M, Paape R, Suckau D, Kruppa G and Hirtz C.
Data in Brief. 2018, Vol 18, June 2018, Pages 1013-1021, https://www.ncbi.nlm.nih.gov/pubmed/29900270
Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches.
Vialaret J, Kadi S, Tiers L,  O’Flynn R, Lehmann S and Hirtz C.
Current Topics in Peptide & Protein Research, 2018 Sous presse, https://www.researchgate.net/publication/331015018
Albumin depletion of human serum to improve quantitative clinical proteomics”.
Fortea J, Carmona-Iragui M, Benejam B, Fernández S, Videla L, Barroeta I, Alcolea D, Pegueroles J, Muñoz L, Belbin O, de Leon MJ, Maceski AM, Hirtz C, Clarimón J, Videla S, Delaby C, Lehmann S, Blesa R, Lleó A.
Lancet Neurol. 2018 : 17(10):860-869, https://www.ncbi.nlm.nih.gov/pubmed/30172624
Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study.
Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, Lehmann S, Gabelle A.
J Alzheimers Dis. 2018;65(1):3-13, https://www.ncbi.nlm.nih.gov/pubmed/30040716
Alzheimer’s Disease: Advances in Drug Development.
Vialaret J, Broutin S, Pugnier C, Santelé S, Jaffuel A, Barnes A, Tiers L, Pelletier L, Lehmann S, Paci A, Hirtz C.
Bioanalysis. 2018 May 1;10(10):723-735, https://www.ncbi.nlm.nih.gov/pubmed/29771137
What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?
Incamps A, Saez-Boiteau C, Tiede SL, Rebillard P, Schulte J, Vialaret J, Beinrucker A, Lehmann S, Hirtz C.
Bioanalysis. 2018 Sep 1;10(17):1383-1399, https://www.ncbi.nlm.nih.gov/pubmed/30207162
Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry.
Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, De Forges H, Firmin N, Guiu S, Jacot W, Lehmann S.
BMC Cancer. 2019 Jan 30;19(1):110, https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5287-z
The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
Molinari N, Roche S, Peoc’h K, Tiers L, Séveno M, Hirtz C, Lehmann S.
Front Mol Neurosci. 2018 Dec 18;11:477, https://www.ncbi.nlm.nih.gov/pubmed/30618622
Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Top-Down Proteomics: A Pilot Study.

 

2017
Maleska A, Hirtz C, Casteleyn E, Villard O, Ducos J, Avignon A, Sultan A, Lehmann S.
Bioanalysis. 2017 Mar;9(5):427-434 (IF:2.7), https://www.ncbi.nlm.nih.gov/pubmed/28220711
Comparison of HbA1c detection in whole blood and dried blood spots using an automated ion-exchange HPLC system.
Lasocki S, Puy H, Mercier G, Lehmann S, Asfar P, Mercat A, Gaillard T, Gergaud S, Lasocki S, Sargentini C, Geneve C, Montravers P, Lefebvre T, Puy H, Mercier G, Nagot N, Delaby C, Hirtz C, Lehmann S, Vialaret J, Chanques G, Jaber S, Asehnoune K, Roquilly A, Dahyot-Fizelier C, Mimoz O, Isslame S, Seguin P, Barbaz M, Ferrandiere M.
Anaesth Crit Care Pain Med. 2017 Sep 14. pii: S2352-5568(17)30089-9. doi: 10.1016 (IF:1.54), https://www.ncbi.nlm.nih.gov/pubmed/28919067
Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial.
Quijada‐Morin N, Garcia F, Lambert K, Walker A‐S, Tiers L, Viaud M, Sauvage F‐X, Hirtz C and Saucier C.
Australian Journal of Grape and Wine Research. (2017) doi: 10.1111/ajgw.12322 (IF:2.635), https://www.researchgate.net/publication/321754809
Strain effect on extracellular laccase activities from Botrytis cinereal.

 

2016

Hirtz C, Vialaret J, Nowak N, Gabelle A, Deville de Périère D and Lehmann S
Bioanalysis (2016).
(IF :3.1) Jan;8(1):43-53, https://www.ncbi.nlm.nih.gov/pubmed/26647646
Absolute quantification of 35 plasma biomarkers in human saliva using targeted mass spectrometry.

Hirtz C, Vialaret J, Gabelle A, Nowak N, Dauvilliers Y and Lehmann S.
Scientific Reports (2016). (IF:5.9) . 2016 May 11;6: 25162, https://www.ncbi.nlm.nih.gov/pubmed/27165941
From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid.

Lehmann S, Vialaret J, Delatour V, Bros P, Brede C, Hirtz C and on behalf of the IFCC Working Group  on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP).
Clin Chem Lab Med (2016). (IF:3) pii: S0009-8981(16)30246-7. doi: 10.1016/j.cca.2016.06.001, https://www.ncbi.nlm.nih.gov/pubmed/27265523
Mass spectrometry proteomics for medical laboratory: what could be the future?

Hassan D, Provansal M, Lehmann S, Rizk M, Moez P, Vialaret J, Hirtz C, Essa A, Agamia H.
Br J Biomed Sci. (IF : 1.3)  2016 Jun 2:1-5, https://www.ncbi.nlm.nih.gov/pubmed/27254308
Proteomic profile of cerebrospinal fluid in patients with multiple sclerosis using two dimensional gel electrophoresis.

Renard D, Gabelle A, Hirtz C, Demattei C, Thouvenot E and Lehmann S.
Journal of Alzheimer Disease (2016). (IF:4.1) 18;54(4):1291-1295, https://www.ncbi.nlm.nih.gov/pubmed/27567848
Cerebrospinal fluid Alzheimer’s disease biomarkers in isolated supratentorial cortical superficial siderosis.

 

2015

Tall ML, Lehmann S, Diouf E, Gérard C,  Filali S, Hirtz C, Gabert L, Sauvinet V, Pirot F, Pivot C.
Ann Pharm Fr (2015). 73(1):43-59. (IF : 0.58), https://www.ncbi.nlm.nih.gov/pubmed/25577016
Injectable preparation of labeled leucine with the carbon 13 for a clinical research program on the Alzheimer disease: Pharmaceutical control of raw materials and the finished product and stability study.

Hirtz C, Lehmann S.
Ann Biol Clin (Paris, 2015). Feb 1;73(1):25-37. (IF :1.9), https://www.ncbi.nlm.nih.gov/pubmed/25582720
Blood sampling using “dried blood spot”: a clinical biology revolution underway?

Bros P, Vialaret J, Barthelemy N, Delatour V, Gabelle A, Lehmann S, Hirtz C.
Front Neurosci (2015). 1;9: 302. (IF :3.7), https://www.ncbi.nlm.nih.gov/pubmed/26388715
Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry.

Morzel M, Neyraud E, Brignot H, Ducoroy P, Jeannin A, Lucchi G, Truntzer C, Canlet C, Tremblay-Franco M, Hirtz C, Gaillard S, Peretti N, Feron G.
J Proteomics (2015). 128:105-12. (IF :3.9), https://www.ncbi.nlm.nih.gov/pubmed/26232109
Multi-omics profiling reveals that eating difficulties developed consecutively to artificial nutrition in the neonatal period are associated to specific saliva composition.

Bros P, Delatour V, Vialaret J, Lalere B, Barthelemy N, Gabelle A, Lehmann S, Hirtz C.
Clin Chem Lab Med (2015). 1;53(10):1483-93. (IF : 3), https://www.ncbi.nlm.nih.gov/pubmed/25719328
Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications.

Lehmann S, Vialaret J, Gras Combe G, Bauchet L, Hanon O, Girard M, Gabelle A, Hirtz C.
Rapid Commun Mass Spectrom (2015). 30;29(20):1917-25. (IF:2.5), https://www.ncbi.nlm.nih.gov/pubmed/26411513
Stable Isotope Labeling by Amino acid in Vivo (SILAV): a new method to explore protein metabolism.

Renard D, Waconge A, Ayrignac X, Mahmoud C, Fourcade G, Azakri S, Le Floch A, Bouly S, Marelli C, Tosi C, Arquizan C, Hirtz C, Gabelle A, Thouvenot E and Lehmann S.
Journal of Alzheimer Disease (2015). (IF:4.1) 50(3):759-64, https://www.ncbi.nlm.nih.gov/pubmed/26757185
Cerebropsinal fluid Alzheimer’s disease biomarkers in cerebral amyloid angiopathy-related inflammation.

Lehmann S and Hirtz C.
Bioanalysis (2015). (IF :3.1) Nov;7(22):2849-51, https://www.ncbi.nlm.nih.gov/pubmed/26600059
What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis?

Bissonnette L, Antoine Y, Tiers L, Hirtz C, Lehmann S, Bissonnette F, Kadoch I.J, Haouzi D, Hamama S.
Journal of Cell Science (2015). (IF:4) Jan 13:0 3;10(3):282-98, https://www.ncbi.nlm.nih.gov/pubmed/26760977
S100A10 plays a crucial role in the acquisition of the human endometrial receptivity phenotype and implantation process.

Barthélemy N, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L, Gabelle A, Junot C, Lehmann S and Becher F.
J.Prot (2015). Research. (IF: 5.46) 5;15(2):667-76, https://www.ncbi.nlm.nih.gov/pubmed/26742856
Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage.

Hirtz C, Vialaret J, Nouadje G, Schraen S, Benlian P, Mary S, Philibert P, Tiers L, Bros P, Delaby C, Gabelle A, Lehmann S.
Clinica Chimica Acta (2015). (IF:3) 15;454:33-8, https://www.ncbi.nlm.nih.gov/pubmed/26707914
Comparison of LC-MRM Mass Spectrometry and semi-automatic Isofocusing approaches for the determination of Apolipoprotein E serotyping.

 

2014
Delaby C, Gabelle A, Meynier P, Loubiere V, Vialaret J, Tiers L, Ducos J, Hirtz C and Lehmann S.
Clin Chem Lab Med (2014). 23:1-7. (IF : 3), https://www.ncbi.nlm.nih.gov/pubmed/24150208
Development and validation of dried matrix spot sampling for the quantitative determination of amyloid beta peptides in cerebrospinal fluid.
Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, Dorey A, Dumurgier J, Hirtz C, Krolak-Salmon P, Laplanche JL, Moreaud O, Peoc’h K, Rouaud O, Sablonnière B, Thouvenot E, Touchon J, Vercruysse O, Hugon J, Gabelle A, Pasquier F, Perret-Liaudet A.
Alzheimers Dement (2014). S1552-5260(13)02495-3. (IF : 14.5), https://www.ncbi.nlm.nih.gov/pubmed/24269268
Impact of harmonization of collection tubes on Alzheimer’s disease diagnosis.

Delaby C, Vialaret J, Bros P, Gabelle A, Lefebvre T, Puy H, Hirtz C and Lehmann S.
EuPA Open Proteomics (2014). Volume 3, Pages 60-67. (IF : 4.1), https://www.researchgate.net/publication/260367860
Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?

Lehmann S, Vialaret J, Seveno M, Tiers L, Gabelle A and  Hirtz C.
Journal of Proteomics & Bioinformatics (2014). (IF : 2.6), http://dx.doi.org/10.4172/jpb.S5-003
Comparison of hydrophobic, lipophilic and immunodepletion pre-fractionation methods for label-free LC-MS/MS identification of biomarkers in human cerebrospinal fluid.
Barthelemy N, Lehmann S, Hirtz C, Gabelle A, Sergeant N, Fenaille F, Vialaret J, Schraen S, Bros P, Tiers L, Delaby C, Junot C, Touchon J, Buee L, Becher F.
Alzheimer’s & Dementia (2014). 10 (no. 4 sup): p. 147. (IF : 14.5), https://www.researchgate.net/publication/266895833  
Detection and Quantification of the Tau Protein and Its Isoforms in the CSF of Alzheimer’s Disease Patients Using Mass Spectrometry.

 

2013

Lehmann S, Hoofnagle A, Hochstrasser D, Brede C, Glueckmann M, Cocho JA, Ceglarek U, Lenz C, Vialaret J, Scherl A, Hirtz C.
Clin Chem Lab Med (2013). Nov 23:1-16. (IF : 3), https://www.ncbi.nlm.nih.gov/pubmed/23183755
Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application.

Lehmann S, Delaby C, Vialaret J, Ducos J, Hirtz C.
Clin Chem Lab Med (2013). 1:1-13. (IF : 3), https://www.researchgate.net/publication/237060490
Current and future use of “dried blood spot” analyses in clinical chemistry.
Lehmann S, Delaby C, Touchon J, Hirtz C and Gabelle A.
Rev. Neurol (2013). 1 6 9. 7 1 9 – 7 2 3. (IF : 0.6), https://www.ncbi.nlm.nih.gov/pubmed/24021316
Biomarkers of Alzheimer’s disease: the present and the future.

 

2011

Lehmann S, Poinot P, Tiers L, Junot C, Becher F, Hirtz C.
Clin Chem Lab Med (2011). Oct 8;50(2):235-42. (IF : 3), https://www.ncbi.nlm.nih.gov/pubmed/24021316
From “Clinical Proteomics” to “Clinical Chemistry Proteomics”: considerations using quantitative mass-spectrometry as a model approach.

Plateforme de Protéomique Clinique

Institute for Regenerative Medicine & Biotherapy (IRMB)
Hôpital Saint Eloi
80 rue Augustin Fliche
34295 MONTPELLIER – Cedex 5
FRANCE

Plan d’accès

Contact

Téléphone : 04 67 33 04 20 

Email